Credit Agricole’s Clovis Oncology, Inc. CLVS Stock Holding History

Credit Agricole’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,900	Closed	-$177K	–	1576
2016 Q3	$177K	Buy	+4,900	New	+$105K	﹤0.01%	1467

Other funds holding CLVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Credit Agricole's CLVS Position: Q4 2017 in Review

Credit Agricole sold out of Clovis Oncology, Inc. (CLVS) in Q4 2017, closing a stake of 19,500 shares — an estimated $1.61M sold.

Credit Agricole first reported a position in CLVS in Q1 2014 and held it in 4 quarters. The position peaked at $1.61M in Q3 2017. 247 funds tracked by Wall St. Rank hold CLVS as of Q4 2017.

Credit Agricole reported no remaining Clovis Oncology, Inc. position as of Q4 2017 after selling out during the quarter.
Credit Agricole sold 19,500 Clovis Oncology, Inc. shares in Q4 2017, an estimated $1.61M.
Credit Agricole first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 4 quarters.
Credit Agricole's Clovis Oncology, Inc. position peaked at $1.61M in Q3 2017.
247 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2017.

Based on Credit Agricole's 13F filing for Q4 2017, filed 13 Feb 2018.